오적산 병용투여가 혈당강하 치료를 받고 있는 제2형 당뇨병 환자의 혈당에 미치는 영향
A Retrospective Study on the Effect of the Co-Administration of Ojeok-san and Hypoglycemic Agents on Blood Glucose Levels in Type 2 Diabetes Mellitus
3
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Objective: This study was conducted to investigate the hypoglycemic effect and safety of Ojeok-san in patients with type 2 Diabetes Mellitus. Methods: We investigated type 2 diabetes mellitus patients at Kyung-Hee University Korean Medical Hospital who were administered Ojeok-san for at least one day between January 2012 and September 2020, basal characteristics and laboratory tests were reviewed retrospectively. The hypoglycemic effect of Ojeok-san was assessed by comparing fasting blood sugar (FBS) and two hours post-prandial plasma glucose (PP2) levels from before and after taking Ojeok-san. Subgroup analyses were conducted according to baseline hypoglycemic treatments and glycated hemoglobin levels (< or ≥6.5%). The safety of Ojeok-san was assessed by comparing levels of aspartate aminotransferase, alanine aminotransferase, γ-glutamyl transferase, blood urea nitrogen, and creatinine. Results: After Ojeok-san administration, FBS and PP2 were significantly reduced to an average of 14.33 mg/dL and 27.67 mg/dL respectively. In the subgroup analysis, PP2 in patients receiving metformin mono therapy was significantly reduced to 28.67 mg/dL, and those receiving a dual therapy of metformin and DPP-4 inhibitor, it was significantly reduced to 32.33 mg/dL. In patients with glycated hemoglobin of lower than 6.5%, FBS was significantly reduced to 12.20 mg/dL, and both FBS and PP2 were significantly reduced, to 15.50 mg/dL and 40.00 mg/dL, respectively, in those with glycated hemoglobin levels of more than 6.5%. The safety profile showed no significant difference after Ojeok-san administration. Conclusions: Ojeok-san has significant hypoglycemic effects in patients with type 2 diabetes mellitus who are also taking hypoglycemic agents.
Abstract
Objective: This study was conducted to investigate the hypoglycemic effect and safety of Ojeok-san in patients with type 2 Diabetes Mellitus. Methods: We investigated type 2 diabetes mellitus patients at Kyung-Hee University Korean Medical Hospital who were administered Ojeok-san for at least one day between January 2012 and September 2020, basal characteristics and laboratory tests were reviewed retrospectively. The hypoglycemic effect of Ojeok-san was assessed by comparing fasting blood sugar (FBS) and two hours post-prandial plasma glucose (PP2) levels from before and after taking Ojeok-san. Subgroup analyses were conducted according to baseline hypoglycemic treatments and glycated hemoglobin levels (< or ≥6.5%). The safety of Ojeok-san was assessed by comparing levels of aspartate aminotransferase, alanine aminotransferase, γ-glutamyl transferase, blood urea nitrogen, and creatinine. Results: After Ojeok-san administration, FBS and PP2 were significantly reduced to an average of 14.33 mg/dL and 27.67 mg/dL respectively. In the subgroup analysis, PP2 in patients receiving metformin mono therapy was significantly reduced to 28.67 mg/dL, and those receiving a dual therapy of metformin and DPP-4 inhibitor, it was significantly reduced to 32.33 mg/dL. In patients with glycated hemoglobin of lower than 6.5%, FBS was significantly reduced to 12.20 mg/dL, and both FBS and PP2 were significantly reduced, to 15.50 mg/dL and 40.00 mg/dL, respectively, in those with glycated hemoglobin levels of more than 6.5%. The safety profile showed no significant difference after Ojeok-san administration. Conclusions: Ojeok-san has significant hypoglycemic effects in patients with type 2 diabetes mellitus who are also taking hypoglycemic agents.
참고문헌 (22)
- 보건복지부, "2019 국민건강통계", 질병관리본부, 171~ (2020)
- Diabetes guideline committee, "Treatment guideline for diabetes 2019", Korean Diabetes Association, 2535~ (2019)
- 2017년 한방의료이용 및 한약소비 실태조사, "보건복지부", 한약진흥재단, 25~47 (2018)
- Korean Diabetes Association, "Diabetes Fact Sheet in Korea 2020", Korean Diabetes Association, ~ (2020)
- 남산당편집국, "對譯證脈, 方藥合編", pp.136~137 (2003), 남산당
- 건강보험심사평가원, "2019 급여의약품 청구 현황", 건강보험심사평가원, 73~ (2020)
- 이남헌, "EBM 기반 구축을 위한 오적산 연구 논문 분석", 대한한의학 방제학회지, 16(2), pp.1~9 (2008), 대한한의학방제학회
- Kim JH, "Effects of Ojuck-san on Hyperlipidemia in Rats", The Korean Society For Oriental Preventive Medicine, 8(2), pp.185~202 (2004)
- 최혜민, "오적산 (五積散)의 고지방식이 마우스 지방축적억제 및 3T3-L1지방세포에서의 비만 조절 기전에 관한 연구", 대한본초학회지, 30(4), pp.121~128 (2015), 대한본초학회
- 건강보험심사평가원, "2020년 상반기 진료비 주요통계", 건강보험심사평가원, 40~ (2020)
- 건강보험심사평가원, "2019년 진료비 주요통계", 건강보험심사평가원, 40~ (2020)
- Korean Diabetes Association, "Diabetes Fact Sheet in Korea 2018", Korean Diabetes Association, ~ (2018)
- Lee SI, "Cheon Jin Chubang Haesul", pp.118~ (1987), Seongbosa
- 윤지연, "五積散의 臨床 活用에 대한 方劑學的 考察", 대한한의학 방제학회지, 20(2), pp.153~164 (2012), 대한한의학방제학회
- 신희라, "오적산 혼합단미엑스산제와 혼합단미연조엑스제의 안전성 평가를 위한 단일 기관, 무작위 배정, 교차 연구", 한방재활의학과학회지, 29(1), pp.63~73 (2019), 한방재활의학과학회[DOI]
- Park JK, "Studies on the Effects of Administration per oral and Aqua - acupuncture with Ojucksan Extract Granule on the pain to mice", J Korean Acupunct Moxib Soc, 9(1), pp.273~291 (1992)
- 한병혁, "TNF-α로 유도된 혈관내피세포의 혈관염증에 미치는 五積散의 억제 효과", 대한본초학회지, 33(4), pp.59~67 (2018), 대한본초학회[DOI]
- 유새롬, "오적산의 추출 용매 차이에 따른 염증 및 염증 관련 질환에 대한 효능 비교", 대한한방내과학회지, 33(4), pp.418~428 (2012), 대한한방내과학회
- 전미혜, "五積散이 子宮筋腫細胞의 死滅과 Cell Apoptosis에 미치는 影響", 대한한방부인과학회지, 16(2), pp.45~55 (2003), 대한한방부인과학회
- 김진원, "뇌경색 환자의 당뇨병성 고지혈증에 대한 五積散加減方 호전 1례", 대한한방내과학회지, 26(1), pp.1~10 (2005), 대한한방내과학회
- Rangwala SM, "Peroxisome proliferator -activated receptor gamma in diabetes and metabolism", Trends in pharmacological sciences, 25(6), pp.331~336 (2004)
- Patel S, "Role of NF-kappa B in the pathogenesis of diabetes and its associated complications", Pharmacological reports, 61(4), pp.595~603 (2009)